Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma

Black patients show inferior survival despite similar cytogenetics and treatment response

Asciminib shows high molecular response, favourable safety in 2L CML-CP

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients

First-line use of tepotinib in METex14 NSCLC: A patient-centered journey

Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for CLL/SLL

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive frontline responses

Empowering cancer care in Africa

Pimicotinib in TGCT demonstrates durable responses and sustained functional improvement

Latest in bladder cancer from the second half of 2025